Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Table 2 Cerebrospinal fluid levels of the biomarker panel in the diagnostic groups

Biomarker	OND	PD	PDD	DLB	AD	p Value
FABP3, pg/ml	521.6 (354.93)	491.5 (231.3)	738.2 (410.0)	836.3 (450.6)^a,b	896.1 (514.07)^c,d	<0.001
α-Syn, pg/ml	1628.0 (705.4)	1846.3 (1216.7)	1381.8 (548.8)	1751.1 (1105.3)	2450.8 (871.24)^c,d,e,f	<0.001
t-tau, pg/ml	225.9 (114.6)	199.8 (73.9)	292.5 (153.5)	356.7 (176.9)^a,b	669.8 (304.0)^c,d,e,f	<0.001
p-tau, pg/ml	45.7 (13.0)	44.6 (9.5)	55.0 (18.8)	60.2 (20.9)^b	106.1 (37.3)^c,d,e,f	<0.001
Aβ_1–42, pg/ml	813.0 (348.7)	792.3 (345.4)	533.8 (168.9)^g,h	562.1 (249.4)^a,b	465.0 (159.3)^c,d	<0.001
Aβ_1–42-positive, <500 pg/ml	7/34 (17.1%)	13/41 (24.1%)	8/11 (42.1%)	15/25 (37.5%)	32/16 (67.7%)	<0.001

Abbreviations: Aβ _1–42 Amyloid-β peptide 1–42, AD Alzheimer’s disease, DLB Dementia with Lewy bodies, FABP3 Fatty acid binding protein 3, heart type, OND Other neurological diseases, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, p-tau ₁₈₁ Phosphorylated tau 181, α-syn α-Synuclein, t-tau Total tau
The cerebrospinal fluid levels of all the tested biomarkers are reported. All data are reported as mean (SD). The p values in the table are relative to the general nonparametric analysis of variance test (across all groups), whereas the footnote callouts are relative to the within-group comparisons
^aDLB vs. OND
^bDLB vs. PD
^cAD vs. OND
^dAD vs. PD
^eAD vs. DLB
^fAD vs. PDD
^gPD vs. PDD
^hPDD vs. OND

ISSN: 1758-9193